Drug safety in COPD revisited: What is the number needed to analyze?

Chest

Volumn 142, Issue 2, 2012, Pages 271-274

  Rabe, Klaus F ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; IPRATROPIUM BROMIDE; LONG ACTING DRUG; METHYLXANTHINE DERIVATIVE; SALMETEROL; SHORT ACTING DRUG; TIOTROPIUM BROMIDE;

ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DISEASE EXACERBATION; DRUG SAFETY; EDITORIAL; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART FAILURE; HUMAN; NUMBERS NEEDED TO TREAT; PRIORITY JOURNAL; STUDY DESIGN;

EID: 84864826489     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-1395     Document Type: Editorial

References (27)

1. Miles MC, Donohue JF, Ohar JA. Optimum bronchodilator combinations in chronic obstructive pulmonary disease: what is the current evidence? Drugs. 2012;72(3):301-308.
2. Hansel TT, Barnes PJ. New drugs for exacerbations of chronic obstructive pulmonary disease. Lancet. 2009;374(9691):744-755.
3. Dalal AA, Candrilli SD, Davis KL. Outcomes and costs associated with initial maintenance therapy with fluticasone propionate-salmeterol xinafoate 250 microg/50 microg combination versus tiotropium in commercially insured patients with COPD. Manag Care. 2011;20(8):46-50, 53-55.
4. Mauskopf JA, Baker CL, Monz BU, Juniper MD. Cost effectiveness of tiotropium for chronic obstructive pulmonary disease:a systematic review of the evidence. J Media Econ. 2010;13(3):403-417.
5. Zaniolo O, Iannazzo S, Pradelli L, Miravitlles M. Pharmacoeconomic evaluation of tiotropium bromide in the longterm treatment of chronic obstructive pulmonary disease (COPD) in Italy. Eur J Health Econ. 2012;13(1):71-80.
6. Johnston AK, Mannino DM, Hagan GW, Davis KJ, Kiri VA. Relationship between lung function impairment and incidence or recurrence of cardiovascular events in a middle-aged cohort. Thorax. 2008;63(7):599-605. (Pubitemid 351969252)
7. Macie C, Wooldrage K, Manfreda J, Anthonisen N. Cardiovascular morbidity and the use of inhaled bronchodilators. Int J Chron Obstruct Pulmon Dis. 2008;3(1):163-169. (Pubitemid 351523729)
8. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003;107(11):1514-1519. (Pubitemid 36378490)
9. Anthonisen NR, Connett JE, Enright PL, Manfreda J;Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med. 2002;166(3):333-339. (Pubitemid 34864422)
10. Cazzola M, Matera MG, Donner CF. Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease. Drugs. 2005;65(12):1595-1610. (Pubitemid 41138983)
11. Celli B, Decramer M, Leimer I, Vogel U, Kesten S, Tashkin DP. Cardiovascular safety of tiotropium in patients with COPD. Chest. 2010;137(1):20-30.
12. Gershon AS, Wang L, To T, Luo J, Upshur RE. Survival with tiotropium compared to long-acting beta-2-agonists in chronic obstructive pulmonary disease. COPD. 2008;5(4):229-234.
13. Hilleman DE, Malesker MA, Morrow LE, Schuller D. A systematic review of the cardiovascular risk of inhaled anticholinergics in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2009;4 :253-263.
14. Kesten S, Jara M, Wentworth C, Lanes S. Pooled clinical trial analysis of tiotropium safety. Chest. 2006;130(6):1695-1703. (Pubitemid 46033421)
15. Lee TA, Pickard AS, Au DH, Bartle B, Weiss KB. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med. 2008;149(6):380-390.
16. Seider N, Abinader EG, Oliven A. Cardiac arrhythmias after inhaled bronchodilators in patients with COPD and ischemic heart disease. Chest. 1993;104(4):1070-1074. (Pubitemid 23306054)
17. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300(12):1439-1450.
18. Wilchesky M, Ernst P, Brophy JM, Platt RW, Suissa S. Bronchodilator use and the risk of arrhythmia in COPD: part 1: Saskatchewan cohort study. Chest. 2012;142(2):298-304.
19. Wilchesky M, Ernst P, Brophy JM, Platt RW, Suissa S. Bronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohort. Chest. 2012;142(2):305-311.
20. Tashkin DP, Celli B, Senn S, et al UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543-1554.
21. Vogelmeier C, Hederer B, Glaab T, et al POET-COPD Investigators. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364(12):1093-1103.
22. Rabe KF. Anticholinergic drugs for the treatment of COPD are safe... are they? Chest. 2010;137(1):1-3.
23. Michele TM, Pinheiro S, Iyasu S. The safety of tiotropium - the FDA's conclusions. N Engl J Med. 2010;363(12):1097-1099.
24. Salpeter SR. Bronchodilators in COPD: impact of beta-agonists and anticholinergics on severe exacerbations and mortality. Int J Chron Obstruct Pulmon Dis. 2007;2(1):11-18. (Pubitemid 46915824)
25. Salpeter SR. Cardiovascular safety of beta(2)-adrenoceptor agonist use in patients with obstructive airway disease: a systematic review. Drugs Aging. 2004;21(6):405-414. (Pubitemid 38612821)
26. FDA Drug Safety Communication. FDA requires postmarket safety trials for Long-Acting Beta-Agonists(LABAs). US Food and Drug Administration website. http://www.fda.gov/Drugs/DrugSafety/ucm251512.htm. Accessed June 2, 2012.
27. Nussbaumer-Ochsner Y, Rabe KF. Systemic manifestations of COPD. Chest. 2011;139(1):165-173.